Science
Innovating gene expression diagnostics at every step
Technology that enables precision medicine for autoimmune disease sufferers.
ANALYTICAL PROCESS
This system uses uniquely sized, adjacently binding, chemically reactive probes (S-Probe and L-Probe) to target genes of interest. Upon binding to the RNA target, the adjacent probes spontaneously ligate and reaction products which can be detected using industry standard instrumentation, such as PCR and capillary electrophoresis.
The Modular Immune Profile (MIP) test
DxTerity is developing a modular immune profile (MIP) for patient stratification ahead of clinical trials, longitudinal monitoring of a patients’ immune health, and for characterization of therapy response in clinical trials and investigational studies.
Systemic Lupus
Erythematosus (SLE)
Rheumatoid
Arthritis (RA)
Multiple
Sclerosis (MS)
Inflammatory Bowel
Disease (IBD)
MIP monitors immune response from a drop
of blood
The MIP panel measures a patient’s relative expression of 51 immune system-related genes within 12 immune system expression modules.
| Type-1 Interferon (IFN-1) |
|
|
IFN-1 status is a prognostic factor for disease severity in SLE, including risk of progression to Lupus Nephritis. Many current and developmental therapeutics target IFN-1 and the JAK/STAT pathway and related pathways. |
| Type-2 Interferon (IFN-γ) |
|
|
IFN-γ plays a key role in T-cell differentiation, immunoregulatory, antiviral and anti-tumor activity. This 3-gene module is being evaluated for therapy response and disease activity in SLE, subtyping in RA, and immunotherapy response prediction in cancer. |
| B-Cell |
|
|
Many common immunosuppressive therapies function through a B-cell depletion mechanism including Rituximab, Ocrevus, and Benlysta. The B-cell module can be used to monitor therapeutic response for B-cell depleting therapies. |
| Plasmablast/Plasma Cell |
|
|
This module has been shown to positively correlate with disease activity in SLE and is impacted by B-cell depleting therapies. Measuring these changes may aid clinicians in the early identification of changes in disease activity or potential disease flare. |
| Neutrophils/Low Density Granulocytes (LDGs) |
|
|
Low density granulocytes are a subset of neutrophils that have been implicated in SLE inflammation and disease progression, including promoting organ damage and increased production of Type-1 Interferon. |
| T-Cells |
|
|
The T-cell genes in MIP are looked at individually to help better understand the underlying mechanism of a patient’s autoimmune disease or cancer. |
| T-Cell Exhaustion |
|
|
In chronic autoimmune disease like SLE, the process of T-cell exhaustion helps inhibit immune response, and exhausted T-cell responses have been associated with better outcomes. T-cell exhaustion mechanisms and markers also play a major role in cancer and how tumors hide from the immune system. |
Partnering to achieve a common goal
Our clinical research platform
DxTerity and clinical researchers share a common goal
To advance the understanding, treatment, and management of immune-mediated disease for improved patient outcomes. To that end, DxTerity is committed to providing integrated, patient-focused services that are designed to promote discovery and rapid product commercialization.
Recruiting for
clinical studies
One of the greatest challenges to conducting efficient, cost-effective clinical studies is obtaining quality clinical specimens. DxTerity is diligently recruiting a nationwide network of patient participants, designing convenient sample collection solutions that encourage patient compliance, and generating reliable test results using a proven genomic platform.
DxTerity provides a turnkey solution for longitudinal studies
Combining proprietary at-home sample collection with next generation eClinical tools, DxTerity provides a turnkey solution for longitudinal studies. The combination of nationwide, online recruiting campaigns and convenient study participation makes enrollment fast and easy. By engaging study participants from the comfort of their homes, DxTerity provides a hub for advancing care in chronic disease.
Thanks to data sharing, a better understanding of patient profiling and selection, it is possible for improved study focus. Appropriate patient selection, coupled with an ability to conveniently obtain samples from patients at home regardless of patient location, expands opportunities to reach a wider representation of patients and reduce study and product development costs.
Thanks to data sharing, a better understanding of patient profiling and selection is possible for improved study focus. Appropriate patient selection, coupled with an ability to conveniently obtain samples from patients at home regardless of patient location, expands opportunities to reach a wider representation of patients and reduce study and product development costs.
Questions?
If you are interested in partnering with DxTerity, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it.
Subscribe to receive the latest information on new developments and products at DxTerity.